These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11742900)

  • 21. [New quinolone. Better effectiveness in problem cases].
    MMW Fortschr Med; 2001 Jul; 143(30):47. PubMed ID: 11524989
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical experience of levofloxacin in community acquired pneumonia].
    Arancibia F; Maldonado A; Torres A
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    Ball P
    Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
    Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of antimicrobial agents for community-acquired lower respiratory tract infections in hospitalised children.
    Esposito S; Blasi F; Allegra L; Principi N;
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):647-50. PubMed ID: 11714047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is reliable in antibiotic therapy of inflammatory bronchopulmonary diseases?].
    Koehler U; Podszus T; von Wichert P
    Internist (Berl); 1998 Dec; 39(12):1264-72. PubMed ID: 10198833
    [No Abstract]   [Full Text] [Related]  

  • 28. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections.
    Bishai W
    Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
    Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
    Iakovlev SV
    Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324
    [No Abstract]   [Full Text] [Related]  

  • 31. [The importance of fluoroquinolones in treating pneumonia in the elderly].
    Belousov IuB; Efremenkova OV; Sokolov AV; Tishenkova IF
    Antibiot Khimioter; 1999; 44(12):23-6. PubMed ID: 10687030
    [No Abstract]   [Full Text] [Related]  

  • 32. Expanding uses of fluoroquinolones: opportunities and challenges.
    Hooper DC
    Ann Intern Med; 1998 Dec; 129(11):908-10. PubMed ID: 9867736
    [No Abstract]   [Full Text] [Related]  

  • 33. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 34. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis in suspected lower respiratory infection and therapy resistance].
    Chalmers JD; Hill AT
    Praxis (Bern 1994); 2012 Feb; 101(3):191-4. PubMed ID: 22294305
    [No Abstract]   [Full Text] [Related]  

  • 36. Consensus among participants for the treatment of community-acquired pneumonia: results of the postsymposium interactive question and answer session.
    Chemotherapy; 2000; 46 Suppl 1():36-9. PubMed ID: 10896482
    [No Abstract]   [Full Text] [Related]  

  • 37. Implementation of new BTS guidelines in acute medical assessment units.
    Beadsworth M; Nye FJ; Beeching NJ
    J Infect; 2003 Jul; 47(1):88-9. PubMed ID: 12850171
    [No Abstract]   [Full Text] [Related]  

  • 38. Sparfloxacin: a review.
    Schentag JJ
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of community-acquired pneumonia.
    Bartlett J
    Chemotherapy; 2000; 46 Suppl 1():24-31. PubMed ID: 10810210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region.
    Memish ZA; Shibl AM; Ahmed QA;
    Int J Antimicrob Agents; 2002; 20 Suppl 1():S1-12. PubMed ID: 12445763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.